Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?

C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays lowered the firm’s price target on C4 Therapeutics to $5 from $10, while maintaining an Overweight rating on the shares. The firm updated its biotechnology price targets as part of its 2026 sector outlook. On December 2, TD Cowen initiated coverage of C4 Therapeutics with a Buy rating but set no price target on the company’s shares. The firm highlighted that the company distin ...